Autopsy report · NCT00726232

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

“Termination of the clinical trial by sponsor.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 10 years before it stopped.
• 73 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Incyte Corporation

Sponsor type

Industry

Conditions

Myeloproliferative Neoplasm (MPN)

Interventions

Ruxolitinib

Participants

73

Sites

4

Countries

Italy, United States

Trials that died the same way

• Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
  “Trial terminated by Sponsor.” (86% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (85% match in meaning)
• TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
  “The Sponsor had decided to terminate this clinical trial due to an insufficient rate of accrual of patients.” (85% match in meaning)
• Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)
  “Sponsor decided to cancel this trial.” (82% match in meaning)
• Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
  “Sponsor decision to terminate the study” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.